Kenvue Inc. (KVUE)

In the absence of randomized trials on the effects of acetaminophen, researchers need to use ‘natural experiments' to develop better guidance for patients.

Cullen Capital Management, LLC disclosed the sale of 6,565,339 shares of Kenvue (KVUE -0.77%) for the period ended Q2 2025. The transaction was valued at an estimated $149.46 million.

Kenvue faces near-term headwinds from Tylenol-autism allegations, macro uncertainty, and segment underperformance, but offers long-term income potential. Recent leadership changes and a focus on core ...

A pair of United States lawmakers sold shares in Tylenol's parent company, Kenvue (NYSE: KVUE), just days before President Donald Trump made controversial remarks linking the painkiller to autism.

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

The CEO behind Tylenol thought he'd found a way to work with the Trump administration. Then everything went off the rails.

U.S. President Donald Trump on Friday repeated his call for pregnant women and young children to stop using popular pain medication Tylenol, defying widespread criticism from medical groups, and offer...

The article highlights the top ten S&P Hi-Yield Aristocrats for September, with nine stocks offering attractive yields and fair pricing for dividend investors. Analyst forecasts project potential net ...

Tylenol may be only the beginning.

Families appealing the dismissal of their lawsuits alleging that Kenvue's Tylenol or generic versions of the pain-relief medication caused their children's autism are asking an appeals court to consid...